Cargando…

Response to ICRF-159 in cell lines resistant to cleavable complex-forming topoisomerase II inhibitors.

We have studied the relationship between expression of genes implicated in mediating resistance to cleavable complex-forming topoisomerase II (topo II) inhibitors and cellular sensitivity to ICRF-159, a 'catalytic' inhibitor of topo II. Overexpression of the membrane transporters, P-glycop...

Descripción completa

Detalles Bibliográficos
Autores principales:	Davies, S. L., Bergh, J., Harris, A. L., Hickson, I. D.
Formato:	Texto
Lenguaje:	English
Publicado:	Nature Publishing Group\|1 1997
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2063389/ https://www.ncbi.nlm.nih.gov/pubmed/9062401

Ejemplares similares

in vitro effects of ICRF 159.
por: Hellmann, K., et al.
Publicado: (1973)

The mutagenic activity of razoxane (ICRF 159): an anticancer agent.
por: Albanese, R., et al.
Publicado: (1985)

Proceedings: Analysis of the antimetastatic action of the antimitotic agent ICRF 159.
por: Hellmann, K., et al.
Publicado: (1974)

Effect of stereoisomers related to ICRF-159 on metastasis of B16 melanoma.
por: Zwilling, B. S., et al.
Publicado: (1981)

ICRF 159-induced cell-cycle perturbation in vitro: its relationship to inhibition of colony-forming ability.
por: Edgar, D. H., et al.
Publicado: (1981)

ICRF-159 enhancement of radiation response in combined modality therapies. II. Differential responses of tumour and normal tissues.
por: Kovacs, C. J., et al.
Publicado: (1979)

Changes in sensitivity to radiation and ICRF 159 during the life of monolayer cultures of EMT6 tumour line.
por: Taylor, I. W., et al.
Publicado: (1977)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines.
por: Houlbrook, S., et al.
Publicado: (1995)

Influence of ICRF 159 and trition WR 1339 on metastases of a rat epithelioma.
por: Pimm, M. V., et al.
Publicado: (1975)

Menogaril, an Anthracycline Derivative, Inhibits DNA Topoisomerase II by Stabilizing Cleavable Complexes
por: Ono, Katsuhiro, et al.
Publicado: (1992)

Evodiamine Stabilizes Topoisomerase I-DNA Cleavable Complex to Inhibit Topoisomerase I Activity
por: Chan, Agnes L.-F., et al.
Publicado: (2009)

Induction of apoptosis in human cancer cell lines by the novel anthracenyl-amino acid topoisomerase I inhibitor NU/ICRF 505.
por: Meikle, I., et al.
Publicado: (1996)

ICRF-159 enhancement of radiation response in combined modality therapies. I. Time/dose relationships for tumour response.
por: Kovacs, C. J., et al.
Publicado: (1979)

Interaction of ICRF 159 with radiation, and its effect on sub-lethal and potentially lethal radiation damage in vitro.
por: Taylor, I. W., et al.
Publicado: (1977)

Casein kinase II–dependent phosphorylation of DNA topoisomerase II suppresses the effect of a catalytic topo II inhibitor, ICRF-193, in fission yeast
por: Nakazawa, Norihiko, et al.
Publicado: (2019)

Development of water-soluble prodrugs of the bisdioxopiperazine topoisomerase IIβ inhibitor ICRF-193 as potential cardioprotective agents against anthracycline cardiotoxicity
por: Bavlovič Piskáčková, Hana, et al.
Publicado: (2021)

Different Susceptibilities of Postmitotic Checkpoint‐proficient and ‐deficient Balb/3T3 Cells to ICRF‐193, a Catalytic Inhibitor of DNA Topoisomerase II
por: Nishida, Keiko, et al.
Publicado: (2001)

Inhibition of DNA topoisomerase II by ICRF-193 induces polyploidization by uncoupling chromosome dynamics from other cell cycle events
Publicado: (1994)

A comprehensive structural analysis of the ATPase domain of human DNA topoisomerase II beta bound to AMPPNP, ADP, and the bisdioxopiperazine, ICRF193
por: Ling, Elise M., et al.
Publicado: (2022)

Characterisation of cytotoxicity and DNA damage induced by the topoisomerase II-directed bisdioxopiperazine anti-cancer agent ICRF-187 (dexrazoxane) in yeast and mammalian cells
por: Jensen, Lars H, et al.
Publicado: (2004)

DNA binding activity of the proximal C-terminal domain of rat DNA topoisomerase IIβ is involved in ICRF-193-induced closed-clamp formation
por: Kawano, Shinji, et al.
Publicado: (2020)

The iCRF Generator: Generating interoperable electronic case report forms using online codebooks
por: de Ridder, Sander, et al.
Publicado: (2020)

Low-level resistance to camptothecin in a human small-cell lung cancer cell line without reduction in DNA topoisomerase I or drug-induced cleavable complex formation.
por: Sorensen, M., et al.
Publicado: (1998)

Relationship between expression of topoisomerase II isoforms and intrinsic sensitivity to topoisomerase II inhibitors in breast cancer cell lines
Publicado: (1996)

Mechanisms regulating resistance to inhibitors of topoisomerase II
por: Ganapathi, Ram N., et al.
Publicado: (2013)

The effects of ICRF-154 in combination with other anticancer agents in vitro.
por: Kano, Y., et al.
Publicado: (1992)

The distribution and expression of the two isoforms of DNA topoisomerase II in normal and neoplastic human tissues.
por: Turley, H., et al.
Publicado: (1997)

Effect of ICRF-187 on doxorubicin-induced myocardial effects in the mouse and guinea pig.
por: Perkins, W. E., et al.
Publicado: (1982)

Differential expression of the topoisomerase II alpha and beta genes in human breast cancers.
por: Sandri, M. I., et al.
Publicado: (1996)

Hyperthermia, thermotolerance and topoisomerase II inhibitors.
por: Kampinga, H. H.
Publicado: (1995)

Enhanced Topoisomerase I Activity and Increased Topoisomerase IIα Content in Cisplatin‐resistant Cancer Cell Lines
por: Minagawa, Yukihisa, et al.
Publicado: (1997)

Biological evaluation of novel thiomaltol-based organometallic complexes as topoisomerase IIα inhibitors
por: Legina, Maria S., et al.
Publicado: (2020)

Metnase Mediates Resistance to Topoisomerase II Inhibitors in Breast Cancer Cells
por: Wray, Justin, et al.
Publicado: (2009)

UHPLC-MS/MS method for analysis of sobuzoxane, its active form ICRF-154 and metabolite EDTA-diamide and its application to bioactivation study
por: Reimerová, Petra, et al.
Publicado: (2019)

Molecular Characterization of Human Papillomavirus Type 159 (HPV159)
por: Marković, Iva, et al.
Publicado: (2021)

Clickable prodrugs bearing potent and hydrolytically cleavable nicotinamide phosphoribosyltransferase inhibitors
por: Sadrerafi, Keivan, et al.
Publicado: (2018)

A new insect cell line engineered to produce recombinant glycoproteins with cleavable N-glycans
por: Mabashi-Asazuma, Hideaki, et al.
Publicado: (2021)

CD26/dipeptidyl peptidase IV enhances expression of topoisomerase II alpha and sensitivity to apoptosis induced by topoisomerase II inhibitors
por: Sato, K, et al.
Publicado: (2003)

Ciprofloxacin is a potential topoisomerase II inhibitor for the treatment of NSCLC
por: KLOSKOWSKI, TOMASZ, et al.
Publicado: (2012)

Discovery of New Catalytic Topoisomerase II Inhibitors for Anticancer Therapeutics
por: Matias-Barrios, Victor M., et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_dn1kp1gd8jcalslsklvta1cfk7